Journal article
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial
Abstract
IMPORTANCE: Muscle-related statin intolerance is reported by 5% to 20% of patients.
OBJECTIVE: To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab.
Authors
Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Češka R; Lepor N
Journal
JAMA, Vol. 315, No. 15,
Publisher
American Medical Association (AMA)
Publication Date
April 19, 2016
DOI
10.1001/jama.2016.3608
ISSN
0098-7484
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsAtorvastatinBiomarkersCholesterol, LDLCreatine KinaseCross-Over StudiesDouble-Blind MethodEzetimibeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMaleMiddle AgedMuscular DiseasesMyalgiaMyositisRhabdomyolysisTime Factors